JANUX THERAPEUTICS INC (JANX)

US47103J1051 - Common Stock

50.82  -6.99 (-12.09%)

After market: 50.84 +0.02 (+0.04%)

JANUX THERAPEUTICS INC

NASDAQ:JANX (1/8/2025, 8:10:56 PM)

After market: 50.84 +0.02 (+0.04%)

50.82

-6.99 (-12.09%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-104%
Sales Q2Q%-82.56%
CRS98.7
6 Month14.9%
Overview
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Ins Owners1.85%
Inst Owners92.96%
Market Cap2.93B
Shares57.66M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts86
Short Float %12.26%
Short Ratio6.04
IPO06-11 2021-06-11
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

JANX Daily chart

Company Profile

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2021-06-11. The company has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Company Info

JANUX THERAPEUTICS INC

10955 Vista Sorrento Parkway, Suite 200

San Diego CALIFORNIA

P: 18587514493

CEO: David Campbell

Employees: 64

Website: https://www.januxrx.com/

JANX Twits

Here you can normally see the latest stock twits on JANX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example